|Day's Range||49.12 - 49.49|
|52 Week Range||36.81 - 50.24|
|PE Ratio (TTM)||12.19|
|Dividend & Yield||1.64 (3.38%)|
|1y Target Est||N/A|
The stock has been on fire.
Vertex (VRTX) has planned to submit a new drug application to the FDA in 3Q17 for a Tezacaftor-Ivacaftor combination treatment for cystic fibrosis.
Drug stocks may be hurt by slashed sales and earnings as prices soften